6 analysts have shared their evaluations of OrthoPediatrics KIDS during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 1 | 2 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 1 | 0 | 0 |
2M Ago | 1 | 1 | 1 | 0 | 0 |
3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated OrthoPediatrics and provided 12-month price targets. The average target is $39.67, accompanied by a high estimate of $50.00 and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.82%.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of OrthoPediatrics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Mike Matson | Needham | Maintains | Buy | $42.00 | $42.00 |
Richard Newitter | Truist Securities | Lowers | Hold | $28.00 | $34.00 |
Richard Newitter | Truist Securities | Raises | Hold | $34.00 | $30.00 |
David Turkaly | JMP Securities | Maintains | Market Outperform | $50.00 | $50.00 |
Mike Matson | Needham | Maintains | Buy | $42.00 | $42.00 |
Mike Matson | Needham | Maintains | Buy | $42.00 | $42.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OrthoPediatrics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of OrthoPediatrics's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OrthoPediatrics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on OrthoPediatrics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind OrthoPediatrics
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
Understanding the Numbers: OrthoPediatrics's Finances
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: OrthoPediatrics's net margin excels beyond industry benchmarks, reaching -14.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): OrthoPediatrics's ROE excels beyond industry benchmarks, reaching -2.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.72%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: OrthoPediatrics's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.